Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patients

Annals of Oncology

Volumn 9, Issue 1, 1998, Pages 55-61

  Vitolo, U ^a   Gaidano, G ^b   Botto, B ^a   Volpe, G ^b   Audisio, E ^a   Bertini, M ^a   Calvi, R ^a   Freilone, R ^a   Novero, D ^b   Orsucci, L ^a   Pastore, C ^b   Capello, D ^b   Parvis, G ^b   Sacco, C ^c   Zagonel, V ^c   Carbone, A ^c   Mazza, U ^b   Palestro, G ^b   Saglio, G ^b   Resegotti, L ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

B DLCL; Clinical correlations; Genetic lesions; Outcome

Indexed keywords

ANTHRACYCLINE;

ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CHROMOSOME 6Q; GENE DELETION; GENE REARRANGEMENT; GENETIC ANALYSIS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; ONCOGENE C MYC; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 6; FEMALE; GENE REARRANGEMENT; GENES, BCL-2; GENES, MYC; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 6844250111     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008201729596     Document Type: Article

References (47)

1. Longo DL. Non Hodgkin's lymphoma. Curr Opin Haematol 1994; 1: 295-302.
2. Devesa SS, Fears T. Non Hodgkin's lymphoma time trends: United States and International data. Cancer Res 1992; 52 (Suppl): 5432-40.
3. Coltman AC, Dahlberg S, Jones ES et al. CHOP is curative in thirty per cent of patients with large cell lymphoma: A twelve year Southwest Oncology Group follow-up. In Skarin AT (ed): Update on Treatment for Diffuse Large Cell Lymphoma. New York: Park Row 1986; 71-7.
4. Longo DL, Devita VT, Duffey PL. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 1991; 9: 25-8.
5. Shipp MA, Yeap BY, Harrington DP et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1991; 8: 84-93.
6. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of advanced diffuse large cell lymphoma. Ann Intern Med 1985; 102: 596-602.
7. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimen for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
8. Freedman AS, Takvorian T, Neuberg D et al. Autologous bone marrow transplantation in poor prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study. J Clin Oncol 1993; 11: 931-6.
9. Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma in first complete remission. A study of 464 patients. J Clin Oncol 1994; 12: 2542-50.
10. Gianni AM, Bregni M, Siena S et al. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336 (18): 1290-7.
11. Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high dose chemotherapy with granulocyte colony stimulating factor and autologous stem cell transplantation support as first line therapy in high risk diffuse large cell lymphoma. J Clin Oncol 1997; 15: 491-8.
12. Harris NL, Jaffe ES, Stein HA et al. Revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
13. Gaidano G, Dalla-Favera R. Lymphomas. Principles & Practice of Oncology, Fifth edition. Cancer 1997; 2131-45.
14. Yunis JJ, Frizzera G, Oken M et al. Multiple recurrent genomic defects in follicular lymphoma: A possible model for cancer. N Engl J Med 1987; 16: 79-84.
15. Gaidano G, Hauptschein RS, Parsa NZ et al. Deletion involving two distinct regions of 6q in B-cell non Hodgkin's lymphoma. Blood 1992; 80: 1781-7.
16. Offit K, Wong G, Filippa DA. Cytogenetic analisys of 434 consecutively ascertained specimens of NHL: Clinical correlations. Blood 1991; 83: 1757-9.
17. Velasquez WS, Jagannath S, Tucker SL et al. Risk classification as the basis for clinical staging of diffuse large cell lymphoma derived from 10-year survival data. Blood 1989; 74: 551-7.
18. Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211-7.
19. Shipp MA, Harrington DP. A predictive model for aggressive NHL: The International Non Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-94.
20. Shipp MA. Can we improve upon the International Index? Ann Oncol 1997; 8 (Suppl 1): S43-7.
21. Yunis JJ, Mayer MG, Arnesen MA. Bcl-2 and other genomic alterations in the prognosis of large cell lymphoma. N Engl J Med 1989; 320: 1047-54.
22. Offit K, LoCoco F, Diane C. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large cell lymphoma. N Engl J Med 1994; 14: 74-80.
23. Tang SC, Visser L, Hepperle B et al. Clinical significance of the bcl-2-MBR gene rearrangement and protein expression in diffuse large cell lymphoma: An analysis of 83 cases. J Clin Oncol 1994; 12: 149-54.
24. Bastard C, Deweindt C, Kerckaert JP. LAZ3 rearrangments in non Hodgkin's lymphoma: Correlation with hystology, immunophenotype, kariotype and clinical outcome in 217 patients. Blood 1994; 83: 2423-7.
25. Romanguera JE, Pugh W, Luthra R et al. The clinical relevance of t(14;18)/bcl-2 rearrangement and del6(q) in diffuse large cell lymphoma and immunoblastic lymphoma. Ann Oncol 1993; 4: 51-4.
26. Knowles DM. Organization and operation of a hematopathology laboratory. In Knowles DM (ed): Neoplastic Hematopathology. Baltimore: Williams & Wilkins 1992; 323-66.
27. The Non-Hodgkin's Lymphoma Classification Project. National Cancer Institut-sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35.
28. Carbone PP, Kaplan HS, Musshof K et al. Report of the Committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1.
29. Connors JM, Fairey R, Klimo P et al. ACOP-B: 6 week chemotherapy and involved field radiotherapy (IFRT) for limited stage large cell lymphoma. Initial result. Proc Am Soc Clin Oncol 1987; 7: 224 (Abstr).
30. O'Reilly SE, Hoskins P, Klimo P et al. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 2: 17-23 (Suppl 1).
31. Bertini M, Freilone R, Vitolo U et al. P-VEBEC new 8 weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994; 5: 895-900.
32. Tirelli U, Zagonel V, Errante D et al. A prospectice study of a new combination of chemotherapy regimen in patients older than 70 years with unfavorable non Hodgkin's lymphoma. J Clin Oncol 1992; 10: 228-36.
33. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
34. Volpe G, Vitolo U, Carbone A et al. Molecular heterogeneity of B-lineage diffuse large cell lymphoma. Genes Chrom Cancer 1996; 16: 21-30.
35. Ye BH, Lista F, Lo Coco F et al. Alterations of bcl-6, a novel zinc-finger gene in diffuse large cell lymphoma. Science 1993; 262: 747-50.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete information. J Am Stat Assoc 1958; 53: 547-81.
37. Vitolo U, Bertini M, Brusamolino E et al. MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992; 10: 219-27.
38. Miller T, Grogan T, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferation antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-6.
39. Stauder R, Eisterer W, Thaler J et al. CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 1995; 85: 2885-99.
40. Lo Coco F, Ye BH, Lista F et al. Rearrangements of the bcl-6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994; 83: 1757-9.
41. Offit K, Jhanwar S. t(3;22)(q27;q11): A novel translocation associated with diffuse non Hodgkin's lymphoma. Blood 1989; 74: 1876-9.
42. Bastard C, Tilly H, Lenormand B et al. Translocation involving band 3q27 and Ig gene regions in non Hodgkin's lymphoma. Blood 1992; 79: 2527-31.
43. Zucca E, Bertoni F, Bosshard G et al. Clinical Significance of bcl-2 (MBR) Jh rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. Ann Oncol 1996; 7: 1023-7.
44. Levine EG, Arthur DC, Frizzera G et al. Cytogenetic abnormalities predict outcome in non-Hodgkin lymphoma. Ann Intern Med 1988; 108: 14-20.
45. Ohshima K, Kikuchi M, Kobari S. Bcl-2 and prognosis of B-cell lymphoma. Leuk Lymph 1991; 5: 305-11.
46. Hill ME, Kenneth AM, Cunninghan DC et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood 1996; 88: 1046-51.
47. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-51.